These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207 [TBL] [Abstract][Full Text] [Related]
4. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. van der Hoorn JW; Kleemann R; Havekes LM; Kooistra T; Princen HM; Jukema JW J Hypertens; 2007 Dec; 25(12):2454-62. PubMed ID: 17984667 [TBL] [Abstract][Full Text] [Related]
5. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130 [TBL] [Abstract][Full Text] [Related]
6. Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice. Yeganeh B; Moshtaghi-Kashanian GR; Declercq V; Moghadasian MH J Nutr Biochem; 2005 Apr; 16(4):222-8. PubMed ID: 15808326 [TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Kleemann R; Princen HM; Emeis JJ; Jukema JW; Fontijn RD; Horrevoets AJ; Kooistra T; Havekes LM Circulation; 2003 Sep; 108(11):1368-74. PubMed ID: 12939225 [TBL] [Abstract][Full Text] [Related]
8. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Choudhury RP; Rong JX; Trogan E; Elmalem VI; Dansky HM; Breslow JL; Witztum JL; Fallon JT; Fisher EA Arterioscler Thromb Vasc Biol; 2004 Oct; 24(10):1904-9. PubMed ID: 15319266 [TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs. van Vlijmen BJ; Pearce NJ; Bergö M; Staels B; Yates JW; Gribble AD; Bond BC; Hofker MH; Havekes LM; Groot PH Arzneimittelforschung; 1998 Apr; 48(4):396-402. PubMed ID: 9608883 [TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Raffai RL; Loeb SM; Weisgraber KH Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):436-41. PubMed ID: 15591220 [TBL] [Abstract][Full Text] [Related]
13. Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Wang Y; Zhao X; Jin H; Wei H; Li W; Bu D; Tang X; Ren Y; Tang C; Du J Arterioscler Thromb Vasc Biol; 2009 Feb; 29(2):173-9. PubMed ID: 18988885 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Merhi-Soussi F; Kwak BR; Magne D; Chadjichristos C; Berti M; Pelli G; James RW; Mach F; Gabay C Cardiovasc Res; 2005 Jun; 66(3):583-93. PubMed ID: 15914123 [TBL] [Abstract][Full Text] [Related]
15. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Hogue JC; Lamarche B; Tremblay AJ; Bergeron J; Gagné C; Couture P Metabolism; 2008 Mar; 57(3):380-6. PubMed ID: 18249211 [TBL] [Abstract][Full Text] [Related]
16. Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice. Atkinson RD; Coenen KR; Plummer MR; Gruen ML; Hasty AH Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E284-90. PubMed ID: 18029445 [TBL] [Abstract][Full Text] [Related]
17. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Delsing DJ; Offerman EH; van Duyvenvoorde W; van Der Boom H; de Wit EC; Gijbels MJ; van Der Laarse A; Jukema JW; Havekes LM; Princen HM Circulation; 2001 Apr; 103(13):1778-86. PubMed ID: 11282910 [TBL] [Abstract][Full Text] [Related]
18. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency. Ruel IL; Lamarche B; Mauger JF; Badellino KO; Cohn JS; Marcil M; Couture P Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2600-7. PubMed ID: 16224048 [TBL] [Abstract][Full Text] [Related]
19. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886 [TBL] [Abstract][Full Text] [Related]
20. [Pleiotropic effect of the micronized fenofibrate: the reduction of plasma chlamydia pneumoniae antibody levels in patients with coronary artery disease]. Márk L; Márki-Zay J; Orosz I; Kondacs A; Erdei F; Katona A Orv Hetil; 2003 Apr; 144(16):765-8. PubMed ID: 12778627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]